Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic

Sexually Transmitted Infections

Volumn 89, Issue 2, 2013, Pages 133-137

  Hamsikova, Eva ^a   Ludvikova, Viera ^a   Stasikova, Jana ^a   Tachezy, Ruth ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADULT; AGED; ARTICLE; CHILD; CZECH REPUBLIC; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; POPULATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SERUM; VACCINATION; VIRUS PARTICLE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84874604482     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2012-050486     Document Type: Article

References (30)

1. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22:2675-86.
2. Bouvard V, Baan R, Straif K, et al; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogensePart B: biological agents. Lancet Oncol 2009; 10:321-2.
3. de Sanjose S, Quint WG, Alemany L, et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56.
4. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26 (Suppl 10):K17-28.
5. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Suppl 3): S35-41.
6. Ho GY, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13:110-16.
7. Safaeian M, Porras C, Schiffman M, et al; Costa Rican Vaccine Trial Group. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102:1653-62.
8. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009; 8:1663-79.
9. Kriz B. Multipurpose serological surveyeits philosophy and objectives in the Czech Republic. Cent Eur J Public Health 2003; 11:S4-6.
10. Smith EM, Ritchie JM, Pawlita M, et al. Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 2007; 120:825-32.
11. Hrbacek J, Urban M, Hamsikova E, et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer 2011; 11:53.
12. Standardization methods. In: Gail MH, Benichou J, eds. Encyclopedia of Epidemiologic Methods. 1st edn. Chichester: John Wiley & Sons Ltd, 2000:871-83.
13. Gorander S, Lagergard T, Romanik M, et al. Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland. Clin Vaccine Immunol 2008; 15:675-80.
14. Hamsikova E, Ludvíková V, Smahel M, et al. Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int J Cancer 1998; 77:689-94.
15. Marais DJ, Rose RC, Lane C, et al. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. J Med Virol 2000; 60:403-10.
16. Dunne EF, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 in children. J Infect Dis 2005; 191:1817-19.
17. Cason J, Mant CA. High-risk mucosal human papillomavirus infections during infancy & childhood. J Clin Virol 2005; 32(Suppl 1):S52-8.
18. Syrjanen S. Current concepts on human papillomavirus infections in children. APMIS 2010; 118:494-509.
19. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200:166-71.
20. Steele J, Collins S, Wen K, et al. Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay. Clin Vaccine Immunol 2008; 15:1387-90.
21. Vaccarella S, Franceschi S, Clifford GM, et al. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on cancer HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2010; 19:2379-88.
22. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
23. Syrjanen S, Waterboer T, Sarkola M, et al. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 2009; 90:1515-26.
24. Newall AT, Brotherton JM, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008; 46:1647-55.
25. Markowitz LE, Sternberg M, Dunne EF, et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National health and Nutrition Examination survey 2003-2004. J Infect Dis 2009; 200:1059-67.
26. Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog 2008; 4: e1000091.
27. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:2036-43.
28. Vardas E, Giuliano AR, Goldstone S, et al. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis 2011; 203:58-65.
29. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197:279-82.
30. Munoz N, Mendez F, Posso H, et al; Instituto Nacional de Cancerologia HPV Study Group. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190:2077-87.